- Home
- INBK vs TLSI Comparison
INBK vs TLSI Comparison
Compare INBK & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- TLSI
- Stock Information
- Founded
- INBK 1999
- TLSI 2010
- Country
- INBK United States
- TLSI United States
- Employees
- INBK N/A
- TLSI N/A
- Industry
- INBK Major Banks
- TLSI Medical Specialities
- Sector
- INBK Finance
- TLSI Health Care
- Exchange
- INBK Nasdaq
- TLSI Nasdaq
- Market Cap
- INBK 196.2M
- TLSI 204.0M
- IPO Year
- INBK N/A
- TLSI N/A
- Fundamental
- Price
- INBK $27.59
- TLSI $4.89
- Analyst Decision
- INBK Buy
- TLSI Strong Buy
- Analyst Count
- INBK 4
- TLSI 5
- Target Price
- INBK $34.50
- TLSI $10.90
- AVG Volume (30 Days)
- INBK 45.0K
- TLSI 153.7K
- Earning Date
- INBK 07-23-2025
- TLSI 08-13-2025
- Dividend Yield
- INBK 0.86%
- TLSI N/A
- EPS Growth
- INBK 27.37
- TLSI N/A
- EPS
- INBK 2.40
- TLSI N/A
- Revenue
- INBK $114,609,000.00
- TLSI $32,141,000.00
- Revenue This Year
- INBK $5.36
- TLSI $55.52
- Revenue Next Year
- INBK $17.09
- TLSI $54.76
- P/E Ratio
- INBK $11.57
- TLSI N/A
- Revenue Growth
- INBK 20.13
- TLSI 46.20
- 52 Week Low
- INBK $19.54
- TLSI $3.50
- 52 Week High
- INBK $43.27
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- INBK 63.75
- TLSI 42.89
- Support Level
- INBK $27.09
- TLSI $4.85
- Resistance Level
- INBK $28.51
- TLSI $5.11
- Average True Range (ATR)
- INBK 0.90
- TLSI 0.30
- MACD
- INBK 0.07
- TLSI -0.03
- Stochastic Oscillator
- INBK 82.27
- TLSI 13.45
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.